CL2015001237A1 - Anticuerpos anti-receptor de procineticinas (prokr) y usos de los mismos. - Google Patents

Anticuerpos anti-receptor de procineticinas (prokr) y usos de los mismos.

Info

Publication number
CL2015001237A1
CL2015001237A1 CL2015001237A CL2015001237A CL2015001237A1 CL 2015001237 A1 CL2015001237 A1 CL 2015001237A1 CL 2015001237 A CL2015001237 A CL 2015001237A CL 2015001237 A CL2015001237 A CL 2015001237A CL 2015001237 A1 CL2015001237 A1 CL 2015001237A1
Authority
CL
Chile
Prior art keywords
procineticin
prokr
antibodies
receptor
procineticin receptor
Prior art date
Application number
CL2015001237A
Other languages
English (en)
Inventor
Lynn Macdonald
Michael L Lacroix-Fralish
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of CL2015001237A1 publication Critical patent/CL2015001237A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Anesthesiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
CL2015001237A 2012-11-13 2015-05-08 Anticuerpos anti-receptor de procineticinas (prokr) y usos de los mismos. CL2015001237A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261725704P 2012-11-13 2012-11-13
US201361825112P 2013-05-20 2013-05-20

Publications (1)

Publication Number Publication Date
CL2015001237A1 true CL2015001237A1 (es) 2015-08-28

Family

ID=49667597

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015001237A CL2015001237A1 (es) 2012-11-13 2015-05-08 Anticuerpos anti-receptor de procineticinas (prokr) y usos de los mismos.

Country Status (18)

Country Link
US (3) US20140134189A1 (es)
EP (1) EP2920211A1 (es)
JP (1) JP2016502520A (es)
KR (1) KR20150084007A (es)
CN (1) CN104781280A (es)
AU (1) AU2013345018A1 (es)
BR (1) BR112015010691A2 (es)
CA (1) CA2891327A1 (es)
CL (1) CL2015001237A1 (es)
CO (1) CO7400866A2 (es)
EA (1) EA201590877A1 (es)
HK (1) HK1210182A1 (es)
IL (1) IL238629A0 (es)
MX (1) MX2015005546A (es)
PH (1) PH12015500903A1 (es)
SG (1) SG11201502933UA (es)
WO (1) WO2014078306A1 (es)
ZA (1) ZA201502516B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI703156B (zh) * 2015-01-30 2020-09-01 學校法人埼玉醫科大學 抗ａｌｋ２抗體
SG11202109163YA (en) * 2019-02-26 2021-09-29 Sorrento Therapeutics Inc Antigen binding proteins that bind bcma

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5891720A (en) 1997-04-17 1999-04-06 Millennium Pharmaceuticals, Inc. Isolated DNA encoding a novel human G-protein coupled receptor
EP1147136A4 (en) 1998-12-10 2003-04-16 Synaptic Pharma Corp DNA CODED FOR A MAMMAL RECEPTOR (fb41a) AND THEIR USE
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
WO2001036471A2 (en) 1999-11-17 2001-05-25 Arena Pharmaceuticals, Inc. Endogenous and non-endogenous versions of human g protein-coupled receptors
US7045299B2 (en) 2000-07-18 2006-05-16 Takeda Pharmaceutical Company Limited Physiologically active peptide and use thereof
US6902902B2 (en) 2001-11-27 2005-06-07 Arena Pharmaceuticals, Inc. Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders
US7297503B2 (en) 2002-10-25 2007-11-20 Molecular Devices Corporation Methods of identifying reduced internalization transmembrane receptor agonists
DE10229379A1 (de) 2002-06-26 2004-01-29 Schering Ag EG-VEGF Rezeptor Antagonisten
WO2004087054A2 (en) 2003-03-25 2004-10-14 The Regents Of The University Of California Methods for modulating gastric secretion using prokineticin receptor antagonists.
GB0320238D0 (en) 2003-08-29 2003-10-01 Medical Res Council Treatment of disease
KR20080006564A (ko) 2005-03-24 2008-01-16 얀센 파마슈티카 엔.브이. 프로키네티신 1 수용체 길항제
DK2374818T3 (da) 2006-06-02 2013-01-21 Regeneron Pharma Højaffinitetsantistoffer mod human IL-6-receptor
NO347649B1 (no) 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
ITRM20070182A1 (it) * 2007-04-03 2008-10-04 Univ Roma Antagonisti dei recettori delle prochineticine derivati di essi e loro uso
JP5425056B2 (ja) 2007-05-15 2014-02-26 エフ．ホフマン−ラ ロシュ アーゲー Ｇタンパク質共役受容体（ｇｐｃｒ）に対する抗体
WO2009042765A1 (en) 2007-09-25 2009-04-02 The Regents Of The University Of California Methods of modulating prokineticin 2 for treatment of stress response and anxiety-related disorders
WO2010077976A2 (en) * 2008-12-17 2010-07-08 The Regents Of The University Of California Prokineticin receptor antagonists and uses thereof
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
JO3375B1 (ar) * 2010-11-08 2019-03-13 Regeneron Pharma أجسام مضادة بشرية للجين a1 الشبيه بعامل النخر الورمي (tl1a)
ITMI20111225A1 (it) * 2011-06-30 2012-12-31 Fond I R C C S Istituto Neur Ologico Carlo Uso di antagonisti non peptidici dei recettori per le prokineticine per la terapia di malattie autoimmuni o con componente autoimmune, o di malattie disimmuni o con componente disimmune

Also Published As

Publication number Publication date
WO2014078306A1 (en) 2014-05-22
EA201590877A1 (ru) 2015-09-30
CA2891327A1 (en) 2014-05-22
EP2920211A1 (en) 2015-09-23
US9951132B2 (en) 2018-04-24
BR112015010691A2 (pt) 2017-08-22
US20180208656A1 (en) 2018-07-26
PH12015500903A1 (en) 2015-07-13
ZA201502516B (en) 2016-01-27
SG11201502933UA (en) 2015-05-28
HK1210182A1 (en) 2016-04-15
US20140134189A1 (en) 2014-05-15
JP2016502520A (ja) 2016-01-28
US20150266957A1 (en) 2015-09-24
KR20150084007A (ko) 2015-07-21
IL238629A0 (en) 2015-06-30
MX2015005546A (es) 2015-08-05
CO7400866A2 (es) 2015-09-30
AU2013345018A1 (en) 2015-05-14
CN104781280A (zh) 2015-07-15

Similar Documents

Publication Publication Date Title
BR112015004397A2 (pt) formulações de anticorpos de receptor anti-prolactina.
CO7020859A2 (es) Anticuerpos anti-cd134 (ox40) y usos de los mismos
CO6821892A2 (es) Anticuerpos anti-angptl3 y usos de los mismos
CO6940383A2 (es) Anticuerpos anti-erbb3 y usos de los mismos
CL2016000251A1 (es) Anticuerpos anti-activina y usos de los mismos
BR112015001459A2 (pt) anticorpos anti-kit e usos dos mesmos.
CO7061078A2 (es) Compuestos de enediino, conjugados de los mismos y sus usos y metodos
CL2015001924A1 (es) Anticuerpos anti-pdgfr-beta y usos relacionados.
DK2997134T3 (da) Human anvendelse af genmanipulerede kimære antigenreceptor-(car)-t-celler
BR112014001030A2 (pt) anticorpos anti-receptor alfa de folato e usos destes
IL237576A0 (en) Multi-chain chimeric antigen receptor and uses thereof
EP2820506A4 (en) TILT STAND FOR ONE DEVICE
CO6940376A2 (es) Anticuerpos anti-psgl-1 y usos de los mismos
BR112015002790A2 (pt) anticorpos asgpr e usos dos mesmos.
EP2770954A4 (en) INTERVERTEBRAL DEVICE
EP2771126A4 (en) FURNACE
EP2854670A4 (en) BONE CONNECTION DEVICE
EP2842000A4 (en) Developing device
CL2015001266A1 (es) Anticuerpos de antihemaglutinina y métodos de uso.
EP2862674A4 (en) BALL BEAM DEVICE
EP2665707A4 (en) ANTAGONISTS OF THE MINERALOCORTICOID RECEPTOR
CL2014002019A1 (es) Anticuerpos anti - asic1; composicion farmaceutica que lo comprende y usos de los mismos.
EP2882400A4 (en) reconstitution
EP2912430A4 (en) CONTRAPTION
EP2867538A4 (en) ANTI SWIRL DEVICE